Instant Insight: Kidney Profile and Cystatin C

Instant Insight: Kidney profile and Cystatin C (PODCAST TRANSCRIPT)

[00:00:00] Welcome to Healthier World with Quest Diagnostics. Our goal is to prompt action from Insight as we keep you up to date on current clinical and diagnostic topics in cardiovascular, metabolic, endocrine, and wellness medicine.

[00:00:18]

[00:00:18] (keep) Welcome to a special episode designed to give you instant insights into the utilization of the kidney profile. (how the kidney profile alignes with CKD guidelines which were updated in 2024 by KDIGO, which stands for Kidney disease improving global outcomes)

[00:00:26] I'm Dr. Mason Lasko, a researcher by training with a passion for learning. And I'm here with some information on how the kidney profile aligns with the CKD guidelines that were updated in 2024 by Which stands for kidney disease, improving global outcomes.

[00:00:42] More than one in seven. Us adults are estimated to have CKD and early stages of CKD are often silent. In fact 90% of people who have CKD don't know, they have it. The majority of patients are missed during these early stages. When the condition can actually be managed and prevented using diet, lifestyle, and medications. The top two risk factors for CKD are hypertension and diabetes.

[00:01:08] So screening these two populations is crucial and the proper assessment of CKD.

[00:01:13] In fact screening, hypertensive and diabetic individuals for CKD is a quality metrics set forth by the healthcare effectiveness data and information set, or Hetus. Given that 10 to 12% of people have diabetes and approximately 50% have hypertension screening for CKD should be done in approximately 60% of our population. But many of these high risk individuals are not receiving guideline recommended screening.

[00:01:40] That's why quest offers the kidney profile, which includes the two guideline recommended tests for staging, CKD, and meets the quality metrics needed for Hetus.

[00:01:50] CKD can be caused by the presence of kidney damage. which was assessed using a urine albumin creatinine ratio or by decreased function, which is assessed using an EG fr.

[00:02:01] Let's first start by talking about kidney damage. We can think of this as structural damage to the kidneys.

[00:02:08] (The kidneys function to filter our blood and allow proteins that should be in our blood to remain in the blood, while pulling proteins out of the blood to be excreted in the urine. If your kidneys have structural damage, but proteins that dont typically leak out into the urine will be found in the urine. the component of the kidney profile that assesses structural damage is called a urine albumin creatinine ratio. importantly, a lot of providers are leaving out this test when assessing patients for CKD, so essentially missing half of the story by excluding this test. so thats structure--what about function? to test for functional damage of the kidneys, we measure what we call an eGFR, which stands for ) the kidney functions to filter out blood and allow proteins that should be in the blood to remain in the blood. What pulling out proteins that should not be in the blood to be excreted in the urine. So if your kidneys have structural damage proteins, that don't typically leak out into the urine,

[00:02:24] will be found in the urine. The component of the kidney profile that assesses structural damage is called a urine albumin creatinine ratio. Importantly,

[00:02:33] a lot of providers are leaving this out when assessing patients for CKD. So essentially missing half the story by excluding this test. So that's structure. What about function? To test for functional damage of the kidneys. We measure what we call an EG fr, which stands for estimated glomerular filtration rate. An ETFR is a blood test

[00:02:54] that measures how well your kidneys filter out proteins. That should be filtered out. So when the kidneys are functioning, well, protein levels in the body are just right. And an EG fr can be estimated using two proteins. Most of the time and the EGFRs calculated based on a protein called creatine. And creatinine is a waste product in the body that comes from the breakdown of muscle tissue and the digestion of proteins from food. Therefore, there are certain populations that don't have an accurate EGF are based on creatine and such as those with lower high meat diets or elder individuals, or those with low muscle mass, such as sarcopenia, for example.

[00:03:33] And of course those with high muscle mass, like bodybuilders.

[00:03:36] In many cases, the serum creatinine can underestimate CKD, staging and underestimates The associated cardiovascular risk with it

[00:03:44] An ETFR can also be calculated based on a different protein called a Cystatin C and Cystatin C is produced by all cells in our body. You may be most familiar with assist stat and see as a followup for individuals who fall into a CKD

[00:03:59] category of stage three, a based on the 2012 guidelines.

[00:04:03] So stagnancy isn't impacted by the same factors that creatinine is such as muscle mass or age.

[00:04:09] However

[00:04:09] so stagnancy, isn't a perfect marker either as it can be influenced by untreated thyroid conditions, steroids, and even certain cancers.

[00:04:18] So since neither protein is the perfect solution for an FGFR by itself. The CKD guidelines from 2024 announced a new estimation for ETFR using both creatinine and Cystatin C.

[00:04:31] Using this new combined HGFR is a more reliable estimate of kidney function , it improves risk assessment. And allows for early detection of CKD.

[00:04:41] Not only does the combined ETFR Better predict risk for CKD, but the 2024 guidelines highlight how using a combined EGF far with creating an ancestor latency, better predicts risk for many other cardio-metabolic conditions as well.

[00:04:56] These conditions include all cause mortality. Uh, cardiovascular mortality end stage renal failure, myocardial infarction, Stroke a AFib. peripheral artery disease, acute kidney injury and progressive CKD.

[00:05:12] Let's walk through this through the lens of a provider. So if a provider is interested in assessing for CKD, They should order a kidney profile, which is a urine albumin, creatinine ratio and an EG fr based on creatinine. If the results show that the patient falls within a CKD stage of three, eight or greater. That's an EGFRs less than 60 or an elevated urine albumin creatinine ratio greater than 30.

[00:05:39] Those patients should follow up with an EGFRs using creatinine and Cystatin C. Additionally, if the patient has a condition where the EGFRs protein may be impacted, these are also patients who should be getting the EGFRs based on both creatinine and Cystatin C.

[00:05:55] (that concludes your instant insights on the utilization of the kidney profile for proper assessment of CKD. The 2024 guidelines emphasize the importance of using both creatinine and cystatin c in estimating eGFR in high risk individuals in order to provide a more refined risk assessment for CKD and other cardiometabolic conditions.By adopting these testing solutions, clinicians will be able to provide comprehensive management. To address both kidney health and overall cardiovascular wellbeing.   The new 2024 guidelines emphasize how the new eGFR equation will improve patient care in high risk individuals for CKD and other car)

[00:05:55] (by using the kidney profile and following up with an eGFR based on creatinine and cystatin c in high risk individual, we will better improve patient care. )

[00:05:55] (not only does combined equation improve accuracy of eGFR which leads to m,ore accurate staging, and as a result, better tracks with risk of adverse outcomes))

[00:05:56] That concludes your instant insight into the utilization of the kidney profile for proper CKD assessment. The 2024 guidelines emphasize the importance of using both creatinine and Cystatin C and estimating any GFR and high risk individuals in order to provide a more refined risk assessment for CKD and other cardio-metabolic conditions. By adopting these testing solutions, clinicians will be able to Provide comprehensive management to address both kidney health and overall cardiovascular wellbeing.

[00:06:29] That's a wrap on this episode of Healthier World with Quest Diagnostics. Please follow us on your favorite podcast app, and be sure to check out Quest Diagnostics Clinical Education Center for more resources, including educational webinars and research publications. Thank you for joining us today as we work to create a healthier world, one life at a time.